相关实验视频

Updated: Jan 15, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

普拉米佩克索尔通过增强自性来改善3xTg-AD小鼠的认知缺陷和突触可塑性损伤

Chunmei Tuo¹, Xiaofan Sui¹, Chenglong Cui¹

¹Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, China.

Experimental neurology

|October 15, 2025

概括

普拉米醇 (PPX) 改善了阿尔茨海默氏症患者的认知缺陷.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

自功能障碍与阿尔茨海默氏症 (AD) 病原发生有关.
目前的自诱导剂缺乏临床疗效或引起副作用.
普拉米佩克索尔 (PPX) 激活大脑自,而不会干扰蛋白质合成.

研究的目的:

为了研究PPX在阿尔茨海默病 (AD) 模型中的神经保护作用.
阐明自在PPX介导的神经保护中的作用.
在AD治疗中识别PPX的潜在分子标.

主要方法:

3xTg-AD小鼠模型用于行为,电生理学和生物化学分析.
评估认知功能,突触可塑性 (LTP),Aβ和tau病理.
测量了自标记物 (LC3-II/LC3-I,p62,Beclin1);使用了生物信息学和分子对接.

主要成果:

PPX显著改善了认知缺陷和海马长期潜能 (LTP) 抑郁症.
PPX降低了粉样β (Aβ) 沉积和陶的过酸化.
PPX激活了自,证据显示LC3-II/LC3-I比率增加,并恢复了Beclin1,其中MAPK1被确定为关键标.

结论:

普拉米醇 (PPX) 在阿尔茨海默氏症 (AD) 模型中显示出神经保护作用.
通过增强自,PPX可以缓解AD病态和认知衰退.
PPX显示出作为AD疾病修饰治疗策略的潜力.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.自自是一种自的过程.认知功能认知功能普拉米佩克索尔 (pramipexole) 是一种药物.

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.